Ashish M. Kamat: Bladder-sparing Therapy for BCG–unresponsive NMIBC
Sabine D. Brookman-May, Professor of Urology at the Ludwig-Maximilians University of Munchen, shared a post by Ashish M. Kamat, Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD Anderson Cancer Center, on X adding:
“Bladder Sparing treatment and sequencing recommendations for patients with BCG unresponsive NMIBC.
- Use the right definition for BCG unresponsiveness.
- Optimal staging needed including imaging and re-TURBT.
- Beyond available treatments counsel patients for clinical trials.”
Quoting Ashish M. Kamat’s post:
“Timely!
Just out from IBCG23 as we wrap up IBCG24:
Bladder-sparing Therapy for BCG–unresponsive NMIBC: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.”
Source: Sabine D. Brookman-May/X and Ashish M. Kamat/X
Authors: Roger Li, Patrick J. Hensley, Shilpa Gupta, Hikmat Al-Ahmadie, Marko Babjuk, Peter C. Black, Maurizio Brausi, Kelly K. Bree, Mario I. Fernández, Charles C. Guo, Amir Horowitz, Donald L. Lamm, Seth P. Lerner, Yair Lotan, Paramananthan Mariappan, David McConkey, Laura S. Mertens, Carmen Mir, Jeffrey S. Ross, Michael O’Donnell, and Ashish M. Kamat.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023